Trial Profile
A Multicenter Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 03 Mar 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 01 Mar 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.